Mersana Therapeutics's total assets for Q3 2024 were $169.53M, a decrease of -5.36% from the previous quarter. MRSN total liabilities were $168.48M for the fiscal quarter, a -1.30% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.